Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
53 hedge funds and large institutions have $60.1M invested in Syros Pharmaceuticals, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 13 reducing their positions, and 29 closing their positions.
2,004% more call options, than puts
Call options by funds: $1.98M | Put options by funds: $94K
76% more capital invested
Capital invested by funds: $34.2M → $60.1M (+$25.9M)
62% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 13
21% less funds holding
Funds holding: 67 → 53 (-14)
48% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$8.64M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$7.31M |
| 3 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
+$5.69M |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$5.62M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$481K |
| 2 |
E
Ergoteles
New York
|
-$259K |
| 3 |
Goldman Sachs
New York
|
-$234K |
| 4 |
Millennium Management
New York
|
-$218K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$103K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Simplex Trading
Chicago,
Illinois
| – | -$114 | -14 | Closed |
|
|
BWL
77
Bogart Wealth LLC
Mclean,
Virginia
| – | +$122 | +15 | New |
|
|
HWMA
78
Heritage Wealth Management (Arizona)
Phoenix,
Arizona
| – | +$146 | +18 | New |
|
|
CUAMC
79
China Universal Asset Management Company
Shanghai,
China
| – | +$479 | +59 | New |
|
SYRS Hedge Fund Activity: Q3 2022 in Review
53 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q3 2022, worth a combined $60.1M — up 76% from $34.2M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of SYRS and 15 opened new positions — a net loss of 14 holders — while 13 trimmed existing stakes and 21 added.
The largest buyer was Artal Group, adding an estimated $8.64M. The largest seller was Oasis Management Company, exiting entirely with an estimated $481K sold.
- 53 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q3 2022, down from 67 in Q2 2022.
- Funds reported $60.1M of Syros Pharmaceuticals, Inc. Common Stock stock for Q3 2022, up 76% quarter-over-quarter.
- 15 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q3 2022 and 29 closed out, a net change of -14 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q3 2022 was Artal Group, an estimated $8.64M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q3 2022 was Oasis Management Company, an estimated $481K sold.
Based on aggregated 13F filings for Q3 2022.